Inhibrx Biosciences’ antibody…
Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 [...]
Regeneron has given up on a CAR-T…
Regeneron has given up on a CAR-T candidate acquired from [...]
Ventyx Biosciences’…
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker [...]
Roche has dropped five Chugai…
Roche has dropped five Chugai candidates from its clinical pipeline, [...]
Recorded at Fierce Biotech Week,…
Recorded at Fierce Biotech Week, this episode of “The Top [...]
Moderna is halting development of…
Moderna is halting development of an mRNA vaccine for congenital [...]
In a mixed interim data drop,…
In a mixed interim data drop, Arcturus Therapeutics has revealed [...]
Alector Therapeutics is shelving a…
Alector Therapeutics is shelving a GSK-partnered antibody after the asset [...]
With $70 million and a phase 2…
With $70 million and a phase 2 ready asset in [...]
“We need to pick a lane here as…
“We need to pick a lane here as a country. [...]